Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKinsey
AstraZeneca
Colorcon
Boehringer Ingelheim

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR PERFOROMIST


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Perforomist

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00633776 ↗ Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT) Withdrawn Dey, L.P. Phase 4 2008-03-01 The purpose of this study is to compare the effects of nebulized formoterol fumarate (Perforomist) to dry-powder inhaler formoterol fumarate (Foradil). Perforomist is a solution that is made into very fine spray (using a nebulizer) that is then breathed in over 10-15 minutes. Foradil is taken in a single quick, deep inhalation.
NCT00633776 ↗ Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT) Withdrawn University of California, Los Angeles Phase 4 2008-03-01 The purpose of this study is to compare the effects of nebulized formoterol fumarate (Perforomist) to dry-powder inhaler formoterol fumarate (Foradil). Perforomist is a solution that is made into very fine spray (using a nebulizer) that is then breathed in over 10-15 minutes. Foradil is taken in a single quick, deep inhalation.
NCT01488019 ↗ Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate) Completed Dey Phase 4 2012-03-01 This study is a multi-center, randomized, placebo-controlled study to evaluate the long-term safety of Perforomist® inhalation therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD). Individual participation is approximately 54 weeks, including 52 weeks of double-blind treatment.
NCT02291016 ↗ COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers Completed Mylan Specialty L.P. N/A 2015-02-01 The purpose of this study is to compare drug delivery and lung function after treatment with formoterol from a nebulizer versus a dry powder inhaler (DPI) in patients recovering from severe exacerbations of COPD. This is to determine if one device is superior in providing better lung function and drug deposition in this clinical setting.
NCT02291016 ↗ COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers Completed University of Tennessee Graduate School of Medicine N/A 2015-02-01 The purpose of this study is to compare drug delivery and lung function after treatment with formoterol from a nebulizer versus a dry powder inhaler (DPI) in patients recovering from severe exacerbations of COPD. This is to determine if one device is superior in providing better lung function and drug deposition in this clinical setting.
NCT02796651 ↗ Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb) Completed Parexel Phase 2 2016-06-30 To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Perforomist

Condition Name

Condition Name for Perforomist
Intervention Trials
Chronic Obstructive Pulmonary Disease (COPD) 2
COPD 2
Chronic Bronchitis 1
Chronic Obstructive Pulmonary Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Perforomist
Intervention Trials
Pulmonary Disease, Chronic Obstructive 5
Lung Diseases, Obstructive 4
Lung Diseases 3
Pulmonary Emphysema 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Perforomist

Trials by Country

Trials by Country for Perforomist
Location Trials
United States 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Perforomist
Location Trials
South Carolina 4
North Carolina 3
Missouri 3
Florida 3
Oregon 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Perforomist

Clinical Trial Phase

Clinical Trial Phase for Perforomist
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Perforomist
Clinical Trial Phase Trials
Completed 5
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Perforomist

Sponsor Name

Sponsor Name for Perforomist
Sponsor Trials
Mylan Inc. 2
Theravance Biopharma 2
University of California, Los Angeles 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Perforomist
Sponsor Trials
Industry 8
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Boehringer Ingelheim
Express Scripts
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.